



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

				·		Washington	
U.S. APPLICATION NO.			FIRST NAMED APPLICANT		ATT	Y. DOCKET NO.	
09/8304	100 -		NADLER	L	500	5907002	
				INTERN	ATIONAL APPLIC	CATION D.	
PAUL T CLARK				Po	CT/US99/2	5438 ³	
CLARK & ELBING		•					
176 FEDERAL ST BOSTON, MA 02				I.A. FILING I		PRIORITY DATE	
				29 OCT	99	29 OCT 98	
l				DATE MA	29	MAY 20	
NOTIFICATION			UIREMENTS UNDE	R 35 U.S.C. 3	71 IN TE		
1 The following ite			ED/ELECTED OFF	-	•		
			applicant or the IB to the U 1.494) 🙀 an Elected Offi			mark	
	sic National Fee		Indication of Small E		,.		
	the internationa		Translation of the international application into English.				
<u> </u>	Declaration of i		\sim	19 amendments into English.			
	Article 19 amer Document.	naments.	Other:	•			
		inary Examinat	ion Report in English and i	ts Annexes, if any	٠.		
			nal Preliminary Examination				
2. Applicant has not the indicated items in prior to 20 or 30 mon	paragraph 3 be	low. The Basic	r 35 U.S.C. 371(f) but has National Fee and the copy oid abandonment.	not filed the follow of the internations	wing indicate al application	ed items and/o n must be filed	
	sic National Fee		Copy of the internation	nal application.			
3. The following item acceptance under 35 l		rnished within t	he period set forth below in	order to complete	e the require	ments for	
·		lication into En	glish. A processing fee wil	l be required if su	bmitted		
late The	r than the appro current transla	opriate 20 or 30 tion is defective	months from the priority de for the reasons indicated or	ate. n the attached Not	ice of Defer	ctive	
	inslation. ssing fee for pro	widing the trans	lation of the application and	d/or the Annexes 1	latan than the	•	
			the priority date (37 CFR 1		ater than the	5	
x c. Oath o	or declaration of application (pre	the inventors, if ferably by the I	n compliance with 37 CFR nternational application num	1.497(a) and (b), aber and internation	onal filing d	ate). A	
date	€.		tted later than the appropriates not comply with 37 CFR				
indi	icated on the att	ached PCT/DO/					
prio	rity date (37 Cl	FR 1:492(e)).	colaration fater than the app	ropriate 20 or 30	monus iron	u une	
 Additional claim for claim fee, are required 	ees of \$ 81.00 d. Applicant m	as a ust submit the a	large entity 🙀 small entity dditional claim fees or cano	, including any rec el the additional c	quired multi laims for wi	ple dependent hich fees are	
due (37 CFR 1.492(g) 5. [37 Applicant has n		•	nce listing pursuant to 37 C	FR 1.821-1.825.	See attache	eði	
PCT/DO/EO/920.							
MONTHS FROM T	HE DATE OF ' TE FOR THE	THIS NOTICE APPLICATIO	4 AND 5 ABOVE MUST OR BY 22 OR 32 MONT N, WHICHEVER IS LAT	THS (where 37 C)	FR 1.495 ar	pplies) FROM	
The time period set ab 1.136(a).	ove may be ext	ended by filing	a petition and fee for extens	sion of time under	the provision	ons of 37 CFR	
Annexes will be cance	lled. A process amendments are	sing fee will be a cancelled since	nexes MUST be submitted to required if submitted later to a translation was not provi- e.	han 20 or 30 mont	ths from the	priority date.	
			United States Patent and Tr lication no. shown above. (ust be maile	ed to the	
	A conv of the	his notice A	<i>IUST be returned</i> w	vith thic room	onse		
Enclosed: PCT/D			e of Defective Translation	we we iwp			
∑ PTO-87			DO/EO/920	nara A Camph	الم		
FORM PCT/DO/EO/9	005 (March 200	1)		para A. Campb			
	(1-1011-011-200)	-,	i elephone:	703-305-3631			

Commissioner for Patents, Box PCT nited States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	`	ATTY. DOCKET NO.			
09/830400	NADLER L		50059/007002		
		INTERNATION	INTERNATIONAL APPLICATION NO.		
PAUL T CLARK CLARK & ELBING	PCT/US99/25438				
176 FEDERAL STREET BOSTON, MA 02110 2214		I.A. FILINO DATE	PRIORITY DATE		
500 TOTA, INIX 02 TTO 22 TT		29 OCT 99	29 OCT 98		
		DATE MAILED:	29 MAY 2001		

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

reason(s):
The application fails to comply with the requirements of 37 CFR 1.821-1.825. This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c). A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as a amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help, (703) 287-0200, for PatentIn software help.

Barbara A. Campbell

Telephone: 703-305-3631

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

FIRST NAMED APPLICANT U.S. APPLICATION NO. ATTY, DOCKET NO. 09/830400 **NADLER** L 50059/007002 INTERNATIONAL APPLICATION NO. PAUL T CLARK PCT/US99/25438 **CLARK & ELBING** 176 FEDERAL STREET I.A. FILING DATE PRIORITY DATE BOSTON, MA 02110 2214 29 OCT 99 29 OCT 98 2.9 MAY 2001 DATE MAILED: NOTIFICATION OF A DEFECTIVE OATH OR DECLARATION This application fails to contain an oath or declaration acceptable under 35 U.S.C. 371(c)(4) for entry into the national stage in the United States of America. The period within which to correct the deficiency noted below and avoid abandonment is set in the accompanying Notification. A new oath or declaration, properly identifying this application (preferably by the international application number and international filing date) is required. The oath or declaration does not comply with 37 CFR 1.497(a),(b) and (f) in that it: is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68. 2. does not identify the application to which it is directed. does not identify the inventor(s). 4. does not identify the citizenship of each inventor. does not state that the person making the oath or declaration believes the named inventor or inventors to be the original and first inventor or inventors of the subject matter which is claimed and for which a patent is sought. FAILURE TO SUBMIT AN OATH OR DECLARATION IN COMPLIANCE WITH 37 CFR 1.497(a) AND (b), AND 1.497(d) WHERE APPROPRIATE, WITHIN THE TIME PERIOD SET WILL RESULT IN FAILURE TO ENTER THE NATIONAL STAGE AND THE ABANDONMENT OF THE APPLICATION. Additionally, the oath or declaration does not comply with 37 CFR 1.63 in that it: does not identify the mailing address of each inventor. If the residence is different from the 1. mailing address, then the city and state or city and foreign country of residence of each inventor must also be given. 2. does not state that the person making the oath or declaration: has reviewed and understands the contents of the application, including the claims, as a. 🖂 amended by any amendment specifically referred to in the oath or declaration. acknowledges the duty to disclose to the Office all information known to the person to be b. 🖂 material to patentability as defined in 37 CFR 1.56. 3. does not identify the foreign application for patent or inventor's certificate for which a claim for priority is made pursuant to 37 CFR 1.55, and any foreign application having a filing date before

Barbara A. Campbell

Telephone: 703-305-3631

that of the application on which priority is claimed, by specifying the application serial number,

country, day, month, and year of its filing.